Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews

Executive Summary

Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.

You may also be interested in...



Inflectra Launch Prep Continues Post-Deadline, Pfizer Says

The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.

Samsung Enters Oncology as Trastuzumab Accepted For EU Review

Samsung Bioepis's trastuzumab has become the South Korean company’s fifth biosimilar candidate to be filed for approval in Europe and also marks its planned entry into the oncology sector in the region.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB001991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel